Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of “acquired resistance” have been discovered and treatments for this specific entity are on the horizon.
- Tsao, A.S., Tang, X.M., Sabloff, B. (2006) Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 1: pp. 231-239
- Rosell, R., Moran, T., Queralt, C. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: pp. 958-967 CrossRef
- Tanaka, T., Matsuoka, M., Sutani, A. (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: pp. 651-655 CrossRef
- Mok, T.S., Wu, Y.L., Thongprasert, S. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: pp. 947-957 CrossRef
- Maemondo, M., Inoue, A., Kobayashi, K. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: pp. 2380-2388 CrossRef
- Jackman, D., Pao, W., Riely, G.J. (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28: pp. 357-360 CrossRef
- Ciardiello, F. (2005) Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 1: pp. 221-234 CrossRef
- Lynch, T.J., Bell, D.W., Sordella, R. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: pp. 2129-2139 CrossRef
- Mitsudomi, T., Morita, S., Yatabe, Y. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: pp. 121-128 CrossRef
- Zhou C, Wu Y-L, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Ann Oncol. 2010;21(suppl. 8). Abstract.
- Paz-Ares, L., Soulieres, D., Melezinek, I. (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14: pp. 51-69 CrossRef
- Riely, G.J., Pao, W., Pham, D. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: pp. 839-844 CrossRef
- Reck, M., Van, Z.N., Gridelli, C. (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 5: pp. 1616-1622 CrossRef
- Heigener D, Gatzemeier U, Schneider CP, et al. Does the type of EGFR activating mutation impact outcomes with erlotinib treatment? Ann Oncol. 2010;21(suppl. 8). Abstract.
- Nardi, V., Azam, M., Daley, G.Q. (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11: pp. 35-43 CrossRef
- Kobayashi, S., Boggon, T.J., Dayaram, T. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: pp. 786-792 CrossRef
- Suda, K., Onozato, R., Yatabe, Y. (2009) EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol 4: pp. 1-4 CrossRef
- Onitsuka, T., Uramoto, H., Nose, N. (2010) Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: pp. 198-203 CrossRef
- Oxnard, G.R., Riely, G.J., Arcila, M.G. (2010) Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol 28: pp. 15s
- Park K, Heo DS, Cho D, et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II study. J Clin Oncol. 2010;28(suppl.). Abstract.
- Mok T, Spigel D, Park K, et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28(suppl.). Abstract.
- Yang CH, Shih JY, Su WP, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUXLung 2). J Clin Oncol. 2010;28(suppl.). Abstract.
- Nishino, M., Jackman, D.M., Hatabu, H. (2010) New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 195: pp. W221-W228 CrossRef
- Miller VA, Hirsh V, Cadranel J, et al. Phase IIB/III double-blind randomized trial of Afatinib (BIBW2992, irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care versus placebo and BSC in patients failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUXLung 1). Ann Oncol. 2020;21(suppl. 8). Abstract.
- Sequist, L.V., Besse, B., Lynch, T.J. (2010) Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: pp. 3076-3083 CrossRef
- McDermott, U., Settleman, J. (2009) Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 27: pp. 5650-5659 CrossRef
- Cipriani, N.A., Abidoye, O.O., Vokes, E. (2009) MET as a target for treatment of chest tumors. Lung Cancer 63: pp. 169-179 CrossRef
- Engelman, J.A., Zejnullahu, K., Mitsudomi, T. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: pp. 1039-1043 CrossRef
- Cappuzzo, F., Marchetti, A., Skokan, M. (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: pp. 1667-1674 CrossRef
- Munshi, N., Jeay, S., Li, Y. (2010) ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9: pp. 1544-1553 CrossRef
- Schiller, J.H., Akerley, W.L., Brugger, W. (2010) : Results from ARQ197-209: a global randomized placebocontrolled phase II clinical trial of erlotinib plus ARQ197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28: pp. 15s CrossRef
- Spigel D, Ervin T, Ramlau R, et al. Randomised multicenter double-blind placebo controlled phase II study evaluating METMAB, an antibody to METreceptor in combination with erlotinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2010;21(suppl. 18). Abstract.
- Morgillo, F., Kim, W.Y., Kim, E.S. (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13: pp. 2795-2803 CrossRef
- Karp, D.D., Paz-Ares, L.G., Novello, S. (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: pp. 2516-2522 CrossRef
- Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(suppl.). Abstract 7500.
- Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
Advances in Therapy
Volume 28, Issue 2 , pp 126-133
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- non-small cell lung cancer
- Industry Sectors